Capsid antigen presentation flags human hepatocytes for destruction after transduction by adeno-associated viral vectors
Open accessThe DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
Adeno-associated virus (AAV) vectors are effective gene delivery vehicles mediating long-lasting transgene expression. Data from a clinical trial of AAV2-mediated hepatic transfer of the Factor IX gene (F9) into hemophilia B subjects suggests that CTL responses against AAV capsid can eliminate transduced hepatocytes and prevent long-term F9 expression. However, the capacity of hepatocytes to present AAV capsid-derived antigens has not been formally demonstrated, nor whether transduction by AAV sensitizes hepatocytes for CTL-mediated destruction. To investigate the fate of capsids after transduction, we engineered a soluble TCR for the detection of capsid-derived peptide:MHC I (pMHC) complexes. TCR multimers exhibited antigen and HLA specificity and possessed high binding affinity for cognate pMHC complexes. With this reagent, capsid pMHC complexes were detectable by confocal microscopy following AAV-mediated transduction of human hepatocytes. Although antigen presentation was modest, it was sufficient to flag transduced cells for CTL-mediated lysis in an in vitro killing assay. Destruction of hepatocytes was inhibited by soluble TCR, demonstrating a possible application for this reagent in blocking undesirable CTL responses. Together, these studies provide a mechanism for the loss of transgene expression and transient elevations in aminotransferases following AAV-mediated hepatic gene transfer in humans and a potential therapeutic intervention to abrogate these limitations imposed by the host T cell response.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Additional characterization showed capsid-specific CD8+ T cells eliminate human hepatocytes after cross-presentation of capsid peptides on MHC I in vitro [89].”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [89]
Citations
Cites
Phenotypic Analysis of Antigen-Specific T Lymphocytes
Altman, J. D., Moss, P. A. H., Goulder, P. J. R., Barouch, D. H., McHeyzer-Williams, M. G., Bell, J. I., McMichael, A. J., & Davis, M. M. (1996) · Science · doi:10.1126/science.274.5284.94 · Cited by 3,544 · cited 1×
“Soluble MHC multimers were developed over a decade ago and have been used successfully to enumerate antigen-specific T cells (11).”
MethodCytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412
Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A., Brunner, M. D., & Panoskaltsis, N. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa063842 · Cited by 2,164 · cited 1×
“In a phase I clinical trial the superagonist anti-CD28 monoclonal antibody TGN1412 induced a massive cytokine storm in human recipients, resulting in multiorgan failure in 6 healthy volunteers at 1/500th the dose that appeared safe in mice and nonhuman primates (44).”
BackgroundManno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163 · cited 7×
“The studies above support previous observations from a human clinical trial of AAV-mediated hepatic gene transfer in which transgene expression was transient and coincided with selflimited elevations in circulating markers of hepatocyte injury (1).”
BackgroundResultInfluentialSelf-citationLIGAND RECOGNITION BY αβ T CELL RECEPTORS
Davis, M. M., Boniface, J. J., Reich, Z., Lyons, D., Hampl, J., Arden, B., & Chien, Y.-H. (1998) · Annual Review of Immunology · doi:10.1146/annurev.immunol.16.1.523 · Cited by 924
Limmer, A., Ohl, J., Kurts, C., Ljunggren, H.-G., Reiss, Y., Groettrup, M., Momburg, F., Arnold, B., & Knolle, P. A. (2000) · Nature Medicine · doi:10.1038/82161 · Cited by 758 · cited 1×
“In this regard, both liver sinusoidal endothelial cells (36) and hepatocytes (37) have been shown to be capable of presenting exogenous antigen, although the molecular details have yet to be completely elucidated.”
BackgroundER–phagosome fusion defines an MHC class I cross-presentation compartment in dendritic cells
Guermonprez, P., Saveanu, L., Kleijmeer, M., Davoust, J., van Endert, P., & Amigorena, S. (2003) · Nature · doi:10.1038/nature01911 · Cited by 753 · cited 1×
“If a preformed capsid engages antigen processing machinery while still within endosomes, then cross-presentation pathways are likely involved (34, 35).”
BackgroundCd8(+) T-Cell Responses to Adeno-Associated Virus Capsid in Humans
Mingozzi, F., Maus, M. V., Hui, D. J., Sabatino, D. E., Murphy, S. L., Rasko, J. E. J., Ragni, M. V., Manno, C. S., Sommer, J., Jiang, H., et al. (2007) · Nature Medicine · doi:10.1038/nm1549 · Cited by 748 · cited 5×
“In addition, AAV2 capsid–specific CD8+ T cells were detectable following vector administration, and their frequency expanded and contracted in temporal correlation with hepatocellular injury (2).”
BackgroundMethodInfluentialSelf-citationEvidence that a Single Peptide–MHC Complex on a Target Cell Can Elicit a Cytolytic T Cell Response
Sykulev, Y., Joo, M., Vturina, I., Tsomides, T. J., & Eisen, H. N. (1996) · Immunity · doi:10.1016/s1074-7613(00)80483-5 · Cited by 703
Phagosomes are competent organelles for antigen cross-presentation
Houde, M., Bertholet, S., Gagnon, E., Brunet, S., Goyette, G., Laplante, A., Princiotta, M. F., Thibault, P., Sacks, D., & Desjardins, M. (2003) · Nature · doi:10.1038/nature01912 · Cited by 699 · cited 1×
“If a preformed capsid engages antigen processing machinery while still within endosomes, then cross-presentation pathways are likely involved (34, 35).”
BackgroundT cell killing does not require the formation of a stable mature immunological synapse
Purbhoo, M. A., Irvine, D. J., Huppa, J. B., & Davis, M. M. (2004) · Nature Immunology · doi:10.1038/ni1058 · Cited by 577 · cited 1×
“In an alternative approach, CTLs have been shown to have detectable increases in intracellular calcium after stimulation by 1 pMHC complex, inducible cytotoxic activity by 1–3 complexes, and maximal calcium flux with mature immunologic synapse formation by 8–10 complexes (42, 43).”
Background
Research works printed but not linked: 1
- Mingozzi, 2003, J. Clin. Invest., 111, 1347, 10.1172/JCI200316887 · doi:10.1172/jci200316887 · Paper page
Cited by
Adeno-Associated Virus (AAV) as a Vector for Gene Therapy
Naso, M. F., Tomkowicz, B., Perry, W. L., & Strohl, W. R. (2017) · BioDrugs · doi:10.1007/s40259-017-0234-5 · Cited by 1,362
Immune responses to AAV vectors: overcoming barriers to successful gene therapy
Mingozzi, F., & High, K. A. (2013) · Blood · doi:10.1182/blood-2013-01-306647 · Cited by 955
“High vector doses may trigger anticapsid CTL responses 4,15,95,128 ; Relatively low-titer antibodies (1:5-1:17) can neutralize large doses of vector.”
InfluentialSelf-citationTherapeutic in vivo gene transfer for genetic disease using AAV: Progress and challenges
Mingozzi, F., & High, K. A. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2988 · Cited by 893
“By contrast, in vitro models of AAV antigen presentation and cytotoxic T lymphocyte-mediated clearance of transduced human cells have been more reliable tools for the study of AAV capsid antigen processing and presentatio”
MethodSelf-citationEmerging issues in AAV-mediated in vivo gene therapy
Colella, P., Ronzitti, G., & Mingozzi, F. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2017.11.007 · Cited by 881
“One important aspect of T cell-mediated immune responses to AAV is that they seem to be detected in a dose-dependent fashion, a result consistent with published in vitro antigen presentation data.(64,65) Above a certain threshold of capsid antigen load, activation of capsid-specific T cells may result in hepatotoxicit…”
BackgroundMethodResultSelf-citationAntigen-presenting cell function in the tolerogenic liver environment
Thomson, A. W., & Knolle, P. A. (2010) · Nature Reviews Immunology · doi:10.1038/nri2858 · Cited by 805
“; however, pre-existing AAV-specific memory T cells restricted long-term transgene expression in transduced hepatocyte”
BackgroundImmune Responses to Viral Gene Therapy Vectors
Shirley, J. L., de Jong, Y. P., Terhorst, C., & Herzog, R. W. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.01.001 · Cited by 788
“However, it was later shown that hepatocytes transduced with AAV present capsid antigen on their surface by MHC I and can be targeted by capsid-specific CD8 T cells.(51) Multiple epitopes have been identified in humans, some of which are conserved among several serotypes.”
BackgroundProgress and prospects: immune responses to viral vectors
Nayak, S., & Herzog, R. W. (2010) · Gene Therapy · doi:10.1038/gt.2009.148 · Cited by 634
AAV Vector Immunogenicity in Humans: A Long Journey to Successful Gene Transfer
Costa Verdera, H., Kuranda, K., & Mingozzi, F. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.12.010 · Cited by 641
“It has been demonstrated that transduced cells and professional APCs present immunogenic epitopes derived from the capsid to cytotoxic CD8 T cells via MHC class I.(40,45,52,60) Cytotoxic T cells are then responsible for driving clearance of AAV-transduced cells, causing inflammation in the target organ, and decreasing…”
BackgroundResultSelf-citationHuman Immune Responses to Adeno-Associated Virus (AAV) Vectors
Ronzitti, G., Gross, D.-A., & Mingozzi, F. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00670 · Cited by 357
“Accordingly, a dosedependent increase in AAV-antigen presented on MHC class I together with higher CD8 T cells activation was reported in vitro (76, 83).”
BackgroundSelf-citationOvercoming Preexisting Humoral Immunity to AAV Using Capsid Decoys
Mingozzi, F., Anguela, X. M., Pavani, G., Chen, Y., Davidson, R. J., Hui, D. J., Yazicioglu, M., Elkouby, L., Hinderer, C. J., Faella, A., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005795 · Cited by 355
“Because the empty capsid is not immunologically inert, however (13, 14), we performed additional experiments using a noninfectious AAV mutant derived from AAV2 (15), showing that the mutant capsid has markedly lower immunogenicity compared to native empty capsids and is nonetheless equally effective at adsorbing antib…”
BackgroundMethodSelf-citationKeeler, A. M., & Flotte, T. R. (2019) · Annual Review of Virology · doi:10.1146/annurev-virology-092818-015530 · Cited by 322
“Similar findings have been demonstrated in subsequent trials with rAAV8-FIX (139), where investigators demonstrated that cytotoxic T cell responses were elicited against specific AAV capsid epitopes and lead to clearance of transduced cells (87).”
ResultUnraveling the complex story of immune responses to AAV vectors trial after trial.
Vandamme, C., Adjali, O., & Mingozzi, F. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.150 · Cited by 234
Self-citationSuccesses and challenges in clinical gene therapy
Kohn, D. B., Chen, Y. Y., & Spencer, M. J. (2023) · Gene Therapy · doi:10.1038/s41434-023-00390-5 · Cited by 184
“These SAEs were attributed to CD8 T cell mediated attack against hepatocytes presenting capsid on MHC [106, 109].”
BackgroundMingozzi, F., & High, K. A. (2017) · Annual Review of Virology · doi:10.1146/annurev-virology-101416-041936 · Cited by 206
Self-citationHan, J. P., Kim, M., Choi, B. S., Lee, J. H., Lee, G. S., Jeong, M., Lee, Y., Kim, E.-A., Oh, H.-K., Go, N., et al. (2022) · Science Advances · doi:10.1126/sciadv.abj6901 · Cited by 191
“…innate and cellular immune responses ( 18 ), and such immunogenicities have been associated with safety issues and prevents long-term therapeutic outcomes because of the lysis of edited cells, which are more threatening in cells having an antigen-presenting function such as hepatocytes ( 19 ).”
Innate Immune Responses to AAV Vectors
Rogers, G. L., Martino, A. T., Aslanidi, G. V., Jayandharan, G. R., Srivastava, A., & Herzog, R. W. (2011) · Frontiers in Microbiology · doi:10.3389/fmicb.2011.00194 · Cited by 178
“Subsequently, it was shown that input capsid-derived peptides are presented by MHC class I www.frontiersin.org September 2011 | Volume 2 | Article 194 | 1 molecules on the surface of hepatocytes following transduction with AAV2 vectors (Pien et al., 2009).”
BackgroundInfluentialAdeno-associated viral vector-mediated immune responses: Understanding barriers to gene delivery
Nidetz, N. F., McGee, M. C., Tse, L. V., Li, C., Cong, L., Li, Y., & Huang, W. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107453 · Cited by 174
Mueller, C., Chulay, J. D., Trapnell, B. C., Humphries, M., Carey, B., Sandhaus, R. A., McElvaney, N. G., Messina, L., Tang, Q., Rouhani, F. N., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci70314 · Cited by 169
“However, the significance of anti-capsid effector T cell responses is unclear, and at least some studies have suggested that they target transduced cells and limit the duration of transgene expression (9, 10).”
BackgroundMartino, A. T., Basner-Tschakarjan, E., Markusic, D. M., Finn, J. D., Hinderer, C., Zhou, S., Ostrov, D. A., Srivastava, A., Ertl, H. C. J., Terhorst, C., et al. (2013) · Blood · doi:10.1182/blood-2012-10-460733 · Cited by 162
“Capsid antigen presentation and CTL assays (killing by effector CD8(1) T cells expanded in vitro from human peripheral blood mononuclear cells) for human hepatocyte cell line HHL5 were performed as described.(22,23) Further details are provided in the supplemental data (“Materials”; see the Blood Web site).”
BackgroundMethodResultInfluentialSelf-citationImmunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer
Arjomandnejad, M., Dasgupta, I., Flotte, T. R., & Keeler, A. M. (2023) · BioDrugs · doi:10.1007/s40259-023-00585-7 · Cited by 159
“Additional characterization showed capsid-specific CD8+ T cells eliminate human hepatocytes after cross-presentation of capsid peptides on MHC I in vitro [89].”
BackgroundSalabarria, S. M., Corti, M., Coleman, K. E., Wichman, M. B., Berthy, J. A., D’Souza, P., Tifft, C. J., Herzog, R. W., Elder, M. E., Shoemaker, L. R., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci173510 · Cited by 159
“However, while these therapies offer a new approach to treat devastating diseases, the immunologic responses to AAV vectors pose a unique challenge that affects their safety and efficacy (5–7).”
BackgroundSubacute Liver Failure Following Gene Replacement Therapy for Spinal Muscular Atrophy Type 1
Feldman, A. G., Parsons, J. A., Dutmer, C. M., Veerapandiyan, A., Hafberg, E., Maloney, N., & Mack, C. L. (2020) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2020.05.044 · Cited by 136
Schulz, M., Levy, D. I., Petropoulos, C. J., Bashirians, G., Winburn, I., Mahn, M., Somanathan, S., Cheng, S. H., & Byrne, B. J. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.01.010 · Cited by 125
Markusic, D. M., Herzog, R. W., Aslanidi, G. V., Hoffman, B. E., Li, B., Li, M., Jayandharan, G. R., Ling, C., Zolotukhin, I., Ma, W., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.172 · Cited by 131
Rogers, G. L., Shirley, J. L., Zolotukhin, I., Kumar, S. R. P., Sherman, A., Perrin, G. Q., Hoffman, B. E., Srivastava, A., Basner-Tschakarjan, E., Wallet, M. A., et al. (2017) · Blood · doi:10.1182/blood-2016-11-751040 · Cited by 131
“Endosomal escape is required for cross-presentation of capsid antigen by hepatocytes.(21,46,47) Removal of phosphorylation sites on the capsid reduces ubiquitination and thus MHC I presentation, thereby reducing the likelihood of transduced hepatocytes being targeted by CD8 T cells.”
Self-citationThe Pleiotropic Effects of Natural AAV Infections on Liver-directed Gene Transfer in Macaques
Wang, L., Calcedo, R., Wang, H., Bell, P., Grant, R., Vandenberghe, L. H., Sanmiguel, J., Morizono, H., Batshaw, M. L., & Wilson, J. M. (2010) · Molecular Therapy · doi:10.1038/mt.2009.245 · Cited by 130
Large-scale recombinant adeno-associated virus production
Kotin, R. M. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr141 · Cited by 123
Meliani, A., Boisgerault, F., Fitzpatrick, Z., Marmier, S., Leborgne, C., Collaud, F., Simon Sola, M., Charles, S., Ronzitti, G., Vignaud, A., et al. (2017) · Blood Advances · doi:10.1182/bloodadvances.2017010181 · Cited by 127
Self-citationImmunogenicity assessment of AAV-based gene therapies: An IQ consortium industry white paper
Yang, T., Braun, M., Lembke, W., McBlane, F., Kamerud, J., DeWall, S. L., Tarcsa, E., Fang, X., Hofer, L., Kavita, U., et al. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.07.018 · Cited by 136
Shao, W., Earley, L. F., Chai, Z., Chen, X., Sun, J., He, T., Deng, M., Hirsch, M. L., Ting, J., Samulski, R. J., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.120474 · Cited by 119
Finn, J. D., Hui, D., Downey, H. D., Dunn, D., Pien, G. C., Mingozzi, F., Zhou, S., & High, K. A. (2010) · Molecular Therapy · doi:10.1038/mt.2009.257 · Cited by 115
Self-citationChallenges Posed by Immune Responses to AAV Vectors: Addressing Root Causes
Hamilton, B. A., & Wright, J. F. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.675897 · Cited by 117
Superior In vivo Transduction of Human Hepatocytes Using Engineered AAV3 Capsid
Vercauteren, K., Hoffman, B. E., Zolotukhin, I., Keeler, G. D., Xiao, J. W., Basner-Tschakarjan, E., High, K. A., Ertl, H. C., Rice, C. M., Srivastava, A., et al. (2016) · Molecular Therapy · doi:10.1038/mt.2016.61 · Cited by 114
Self-citationHareendran, S., Balakrishnan, B., Sen, D., Kumar, S., Srivastava, A., & Jayandharan, G. R. (2013) · Reviews in Medical Virology · doi:10.1002/rmv.1762 · Cited by 113
“f target cell by recombinant AAV may be followed by the vector tides then get loaded onto MHC I molecules and are presented in the transduced host cell [52].”
BackgroundBaruteau, J., Waddington, S. N., Alexander, I. E., & Gissen, P. (2017) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-017-0053-3 · Cited by 110
“The following examples demonstrate why animal experiments provide limited value for predicting effects in human trials: – T-cell mediated cytotoxicity observed in the first haemophilia B trial was not predicted by experiments in mice, dogs or non-human primates (Pien et al 2009).”
BackgroundNienhuis, A. W., Nathwani, A. C., & Davidoff, A. M. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.03.033 · Cited by 99
Koilkonda, R. D., Yu, H., Chou, T.-H., Feuer, W. J., Ruggeri, M., Porciatti, V., Tse, D., Hauswirth, W. W., Chiodo, V., Boye, S. L., et al. (2014) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2013.7630 · Cited by 103
Cell-Mediated Immunity to AAV Vectors, Evolving Concepts and Potential Solutions
Basner-Tschakarjan, E., & Mingozzi, F. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00350 · Cited by 95
“This result is somewhat in contrast with previous data showing that empty capsids do flag transduced cells for T cell recognition (70).”
BackgroundMethodResultInfluentialSelf-citationThe potential of adeno-associated viral vectors for gene delivery to muscle tissue
Wang, D., Zhong, L., Nahid, M. A., & Gao, G. (2014) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2014.871258 · Cited by 98
“demonstrated the presence of capsid epitope-MHC I complexes on the surface of AAV-transduced hepatocytes by confocal microscopy [135].”
Gene Therapy for the Nervous System: Challenges and New Strategies
Maguire, C. A., Ramirez, S. H., Merkel, S. F., Sena‐Esteves, M., & Breakefield, X. O. (2014) · Neurotherapeutics · doi:10.1007/s13311-014-0299-5 · Cited by 110
“Innate immune cells, such as macrophage and liver sinusoidal endothelial cells, can internalize and degrade virus vectors [29]; preexisting antibodies against the wild type virus (from which the vector is derived) can eliminate vector from circulation; and cytotoxic T cells directed against viral antigens [30] or the…”
BackgroundUnderstanding AAV vector immunogenicity: from particle to patient
Dhungel, B. P., Winburn, I. C., Pereira, C. D. F., Huang, K., Chhabra, A., & Rasko, J. E. J. (2024) · Theranostics · doi:10.7150/thno.89380 · Cited by 101
“However, empty capsids may also contribute to the overall number of capsid antigens presented onto MHC class I and may also have an impact on the immunogenicity of AAV vectors [28, 107].”
BackgroundCFTR gene transfer with AAV improves early cystic fibrosis pig phenotypes
Steines, B., Dickey, D. D., Bergen, J., Excoffon, K. J. D. A., Weinstein, J. R., Li, X., Yan, Z., Alaiwa, M. H. A., Shah, V. S., Bouzek, D. C., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.88728 · Cited by 92
“However, it proved to be less efficient in humans (51).”
BackgroundState-of-the-art human gene therapy: part I. Gene delivery technologies.
Wang, D., & Gao, G. (2014) · PubMed · Cited by 117
AAV capsid CD8+ T-cell epitopes are highly conserved across AAV serotypes
Hui, D. J., Edmonson, S. C., Podsakoff, G. M., Pien, G. C., Ivanciu, L., Camire, R. M., Ertl, H., Mingozzi, F., High, K. A., & Basner-Tschakarjan, E. (2015) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2015.29 · Cited by 84
Self-citationGene therapy for haemophilia: a long and winding road
High, K. A. (2011) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2011.04369.x · Cited by 87
Self-citationChowdhury, E. A., Meno‐Tetang, G. M. L., Chang, H. Y., Wu, S., Huang, H. W., Jamier, T., Chandran, J. S., & Shah, D. K. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.01.017 · Cited by 82
Shirley, J. L., Keeler, G. D., Sherman, A., Zolotukhin, I., Markusic, D. M., Hoffman, B. E., Morel, L. M., Wallet, M. A., Terhorst, C., & Herzog, R. W. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.11.011 · Cited by 79
Long, B. R., Veron, P., Kuranda, K., Hardet, R., Mitchell, N., Hayes, G. M., Wong, W. Y., Lau, K., Li, M., Hock, M. B., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2020.12.008 · Cited by 76
Self-citationCurrent status of haemophilia gene therapy
High, K. H., Nathwani, A., Spencer, T., & Lillicrap, D. (2014) · Haemophilia · doi:10.1111/hae.12411 · Cited by 73
Self-citationAdeno-Associated Viruses (AAV) and Host Immunity – A Race Between the Hare and the Hedgehog
Rapti, K., & Grimm, D. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.753467 · Cited by 79
“Cellular immune responses against the capsid (39, 101)”
BackgroundImmunological barriers to haematopoietic stem cell gene therapy
Charlesworth, C. T., Hsu, I., Wilkinson, A. C., & Nakauchi, H. (2022) · Nature reviews. Immunology · doi:10.1038/s41577-022-00698-0 · Cited by 74
Immortalized Human Hepatic Cell Lines for In Vitro Testing and Research Purposes
Ramboer, E., Vanhaecke, T., Rogiers, V., & Vinken, M. (2015) · Methods in Molecular Biology · doi:10.1007/978-1-4939-2074-7_4 · Cited by 61
“Moreover, the HHL cell line proved useful during the development of adeno-associated viral vectors for liver-directed gene therapy (89-91).”
MethodGene Therapy with Helper-Dependent Adenoviral Vectors: Current Advances and Future Perspectives
Vetrini, F., & Ng, P. (2010) · Viruses · doi:10.3390/v2091886 · Cited by 77
“[93].”
Koilkonda, R., Yu, H., Talla, V., Porciatti, V., Feuer, W. J., Hauswirth, W. W., Chiodo, V., Erger, K. E., Boye, S. L., Lewin, A. S., et al. (2014) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.14-15388 · Cited by 65
Raupp, C., Naumer, M., Müller, O. J., Gurda, B. L., Agbandje-McKenna, M., & Kleinschmidt, J. A. (2012) · Journal of Virology · doi:10.1128/jvi.00209-12 · Cited by 64
“Humoral immune responses are generated and memory CD8 T-cell responses have been observed in clinical trials (36, 40, 58).”
BackgroundHigh, K. A., & Aubourg, P. (2012) · Methods in Molecular Biology · doi:10.1007/978-1-61779-370-7_18 · Cited by 60
Self-citationAdeno-associated virus capsid antigen presentation is dependent on endosomal escape
Li, C., He, Y., Nicolson, S., Hirsch, M., Weinberg, M. S., Zhang, P., Kafri, T., & Samulski, R. J. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66611 · Cited by 61
“It should be noted that our finding of decreased antigen presentation by empty virions is inconsistent with a prior observation in which AAV2-empty pulsed target cells were killed by AAV capsid–amplified PBMCs (53).”
InfluentialStrategies to circumvent humoral immunity to adeno-associated viral vectors
Tse, L. V., Moller-Tank, S., & Asokan, A. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.1035645 · Cited by 61
“In this regard, an earlier study has shown that both empty virions and full AAV capsids are capable of flagging hepatocytes for cytotoxic T-lymphocyte (CTL)-mediated destruction, thereby underscoring the importance of reducing antigenic burden by removing empty virions from the formulation [70].”
Gene therapy for Duchenne muscular dystrophy
Ramos, J. N., & Chamberlain, J. S. (2015) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2015.1088780 · Cited by 69
“AAV capsid and transgene-specific responses by effector CD8 cells has been reported in multiple animal models and in humans [37,38,79-86].”
BackgroundFuchs, S. P., & Desrosiers, R. C. (2016) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2016.68 · Cited by 61
Brown, D., Altermatt, M., Dobreva, T., Chen, S., Wang, A., Thomson, M., & Gradinaru, V. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.730825 · Cited by 60
The gene therapy journey for hemophilia: are we there yet?
High, K. A. (2012) · Blood · doi:10.1182/blood-2012-05-423210 · Cited by 55
Self-citationIlyinskii, P. O., Michaud, A. M., Roy, C. J., Rizzo, G. L., Elkins, S. L., Capela, T., Chowdhury, A. C., Leung, S. S., & Kishimoto, T. K. (2021) · Science Advances · doi:10.1126/sciadv.abd0321 · Cited by 56
Uhrig, S., Coutelle, O., Wiehe, T., Perabò, L., Hallek, M. J., & Büning, H. (2011) · Gene Therapy · doi:10.1038/gt.2011.78 · Cited by 60
Boisgerault, F., & Mingozzi, F. (2015) · Current Gene Therapy · doi:10.2174/1566523215666150630121750 · Cited by 54
Self-citationEx vivo editing of human hematopoietic stem cells for erythroid expression of therapeutic proteins
Pavani, G., Laurent, M., Fabiano, A., Cantelli, E., Sakkal, A., Corre, G., Lenting, P. J., Concordet, J.-P., Toueille, M., Miccio, A., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17552-3 · Cited by 49
Humoral immune responses to AAV gene therapy in the ocular compartment
Whitehead, M., Osborne, A., Yu‐Wai‐Man, P., & Martin, K. (2021) · Biological Reviews · doi:10.1111/brv.12718 · Cited by 52
“This effectively clears AAV-transduced cells and thereby decreases expression of a particular transgene product (Mingozzi et al., 2007; Pien et al., 2009).”
Discussing investigational AAV gene therapy with hemophilia patients: A guide
Sidonio, R. F., Pipe, S. W., Callaghan, M. U., Valentino, L. A., Monahan, P. E., & Croteau, S. E. (2020) · Blood Reviews · doi:10.1016/j.blre.2020.100759 · Cited by 54
Viral vectors for gene therapy and gene modification approaches
Merten, O., & Gaillet, B. (2015) · Biochemical Engineering Journal · doi:10.1016/j.bej.2015.09.005 · Cited by 57
An update on gene therapy for lysosomal storage disorders
Nagree, M. S., Scalia, S., McKillop, W. M., & Medin, J. A. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2019.1607837 · Cited by 53
Activation of the Cellular Unfolded Protein Response by Recombinant Adeno-Associated Virus Vectors
Balakrishnan, B., Sen, D., Hareendran, S., Roshini, V., David, S., Srivastava, A., & Jayandharan, G. R. (2013) · PLoS ONE · doi:10.1371/journal.pone.0053845 · Cited by 50
“In AAV2 mediated gene therapy, the concept of capsid protein dependent immunotoxicity is well documented [5,34] and several groups have shown that cellular cytoplasmic surveillance mechanisms such as the NF-kB signalling [35], MYD88 pathway or toll-like receptor (TLR-9) [36,37] signalling influence this process.”
BackgroundThe gene therapy journey for hemophilia: are we there yet?
High, K. A. (2012) · PubMed · doi:10.1182/asheducation-2012.1.375 · Cited by 48
Self-citationModulation of CD8+ T cell responses to AAV vectors with IgG-derived MHC class II epitopes
Hui, D. J., Basner-Tschakarjan, E., Chen, Y., Davidson, R. J., Buchlis, G., Yazicioglu, M., Pien, G. C., Finn, J. D., Haurigot, V., Tai, A., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.166 · Cited by 47
Self-citationA universal system to select gene-modified hepatocytes in vivo
Nygaard, S. C., Barzel, A., Haft, A., Major, A. M., Finegold, M. J., Kay, M. A., & Grompe, M. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad8166 · Cited by 48
Gene therapy strategies for hemophilia: benefits versus risks
Petrus, I., Chuah, M., & VandenDriessche, T. (2010) · The Journal of Gene Medicine · doi:10.1002/jgm.1500 · Cited by 50
Manfredsson, F., Okun, M., & Mandel, R. (2009) · Current Gene Therapy · doi:10.2174/156652309789753400 · Cited by 50
“In the periphery, however, clinical trials for hemophilia B using rAAV2 as the vector have revealed immune responses against the viral capsid that abrogates long-term gene expression [112].”
BackgroundGernoux, G., Gruntman, A. M., Blackwood, M., Zieger, M., Flotte, T. R., & Mueller, C. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.01.004 · Cited by 44
“However, a systemic injection has shown limits due to a capsid-specific cellular immune response observed in high-dose patient groups injected with either rAAV2,(28) rAAV8,(29) or rAAV9(32) and was explained by the presentation of AAV-capsid-derived antigen on major histocompatibility complex class I (MHC I) expressed…”
BackgroundPierce, G. F., & Iorio, A. (2018) · Haemophilia · doi:10.1111/hae.13489 · Cited by 47
Understanding and Tackling Immune Responses to Adeno-Associated Viral Vectors
Verdera, H. C., Unzu, C., Valeri, E., Adriouch, S., González‐Aseguinolaza, G., Mingozzi, F., & Kajaste‐Rudnitski, A. (2023) · Human Gene Therapy · doi:10.1089/hum.2023.119 · Cited by 47
Self-citationMarkmann, S., De, B. P., Reid, J., Jose, C. L., Rosenberg, J. B., Leopold, P. L., Kaminsky, S. M., Sondhi, D., Pagovich, O., & Crystal, R. G. (2018) · Human Gene Therapy · doi:10.1089/hum.2017.203 · Cited by 42
Gene therapy with regulatory T cells: A beneficial alliance
Biswas, M., Kumar, S. R. P., Terhorst, C., & Herzog, R. W. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00554 · Cited by 41
Gene therapy for hemophilia – From basic science to first approvals of “one-and-done” therapies
Herzog, R. W., Kaczmarek, R., & High, K. A. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.043 · Cited by 43
Self-citationDhadwar, S., Kiernan, J., WEN, J., & Hortelano, G. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2010.04116.x · Cited by 41
Pre-Clinical Assessment of Immune Responses to Adeno-Associated Virus (AAV) Vectors
Basner-Tschakarjan, E., Bijjiga, E., & Martino, A. T. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00028 · Cited by 39
Self-citationUncertainty in an era of transformative therapy for haemophilia: Addressing the unknowns
Pierce, G. F. (2020) · Haemophilia · doi:10.1111/hae.14023 · Cited by 39
Present and Future of Adeno Associated Virus Based Gene Therapy Approaches
Ortolano, S., Spuch, C., & Navarro, C. (2012) · Recent Patents on Endocrine, Metabolic & Immune Drug Discovery · doi:10.2174/187221412799015245 · Cited by 35
Measuring Immune Responses to Recombinant AAV Gene Transfer
Martino, A. T., Herzog, R. W., Anegon, I., & Adjali, O. (2012) · Methods in Molecular Biology · doi:10.1007/978-1-61779-370-7_11 · Cited by 36
Haemophilia gene therapy: Progress and challenges
Lhériteau, E., Davidoff, A. M., & Nathwani, A. C. (2015) · Blood Reviews · doi:10.1016/j.blre.2015.03.002 · Cited by 38
“2) [53].”
Differential T cell immune responses to deamidated adeno-associated virus vector
Bing, S. J., Justesen, S. F. L., Wu, W. W., Sajib, A. M., Warrington, S., Baer, A., Thorgrimsen, S., Shen, R., & Mazor, R. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.01.005 · Cited by 40
“It was later shown that transduced cells present capsid-derived epitopes to cytotoxic CD8 T cells via major histocompatibility complex class I (MHC class I).(12) Recent clinical trials using rAAV also indicated that high abundance of CpG motifs in the vector resulted in failure to achieve sustained expression, owing t…”
BackgroundMycophenolate mofetil impairs transduction of single-stranded adeno-associated viral vectors
Montenegro-Miranda, P. S., Bloemendaal, L. T., Kunne, C., de Waart, D. R., & Bosma, P. J. (2011) · Human Gene Therapy · doi:10.1089/hum.2010.222 · Cited by 35
“However, in patients a cytotoxic T lymphocyte (CTL) response toward the AAV2 capsid prevented sustained correction of factor IX deficiency (Manno et al. , 2006; Pien et al. , 2009).”
Li, B., Ma, W., Ling, C., Vliet, K. V., Huang, L.-Y., Agbandje‐McKenna, M., Srivastava, A., & Aslanidi, G. (2015) · Human Gene Therapy Methods · doi:10.1089/hgtb.2015.115 · Cited by 35
Hepatotoxicity in Adeno-Associated Viral Vector Gene Therapy
Jagadisan, B., & Dhawan, A. (2023) · Current Hepatology Reports · doi:10.1007/s11901-023-00624-5 · Cited by 36
“The CD8 + cellular response results in destruction of the transduced cells which was not noted in animal studies [42, 51, 52].”
Hemophilia Gene Therapy: Ready for Prime Time?
VandenDriessche, T., & Chuah, M. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.116 · Cited by 32
Liver-Directed Adeno-Associated Viral Gene Therapy for Hemophilia
Markusic, D. M., & Herzog, R. W. (2013) · Journal of Genetic Syndromes & Gene Therapy · doi:10.4172/2157-7412.s1-009 · Cited by 36
“Human hepatocytes infected with a similar AAV2 vector used in the clinical trial were capable of processing and presenting the capsid epitope on MHCI molecules and were lysed by capsid specific CD8+ T cells [66].”
MethodPreclinical and clinical progress in hemophilia gene therapy
Mátrai, J., Chuah, M., & VandenDriessche, T. (2010) · Current Opinion in Hematology · doi:10.1097/moh.0b013e32833cd4bd · Cited by 36
Clinical and Translational Landscape of Viral Gene Therapies
Yudaeva, A., Kostyusheva, A. P., Kachanov, A., Brezgin, S. A., Ponomareva, N., Parodi, A., Pokrovsky, V. S., Lukashev, A. N., Chulanov, V., & Kostyushev, D. S. (2024) · Cells · doi:10.3390/cells13221916 · Cited by 32
AAV-mediated gene therapy for liver diseases: the prime candidate for clinical application?
van der Laan, L. J. W., Wang, Y., Tilanus, H. W., Janssen, H. L. A., & Pan, Q. (2011) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.548799 · Cited by 33
“Consistently, a recent study showed that antigen presentation by hepatocytes, although modest, was sufficient to flag transduced cells for cytotoxic-T-cell-mediated lysis in vitro [131].”
BackgroundDong, B., Moore, A. R., Dai, J., Roberts, S., Chu, K., Kapranov, P., Moss, B., & Xiao, W. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt404 · Cited by 29
“replication-competent AAV particle (rcAAV), is generally an undesired contaminant, which may be detrimental to the patient and can abrogate long-term transgene expression (4,5).”
Pabinger, I., Ayash‐Rashkovsky, M., Escobar, M. A., Konkle, B. A., Mingot‐Castellano, M. E., Mullins, E. S., Négrier, C., Pan, L., Rajavel, K. S., Yan, B., et al. (2024) · Gene Therapy · doi:10.1038/s41434-024-00441-5 · Cited by 31
Long, B. R., Robinson, T. M., Day, J. R., Yu, H., Lau, K., Imtiaz, U., Patton, K. S., de Hart, G., Henshaw, J., Agarwal, S., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.05.033 · Cited by 31
“19 – 22 Prevailing hypotheses based on early hemophilia B gene therapy trials suggested that such cellular immune responses can result in elimination of transduced hepatocytes, liver transaminase elevation, and transgene-derived protein loss.”
Metadata
- Authors
- Pien, G. C., Basner-Tschakarjan, E., Hui, D. J., Mentlik, A. N., Finn, J. D., Hasbrouck, N. C., Zhou, S., Murphy, S. L., Maus, M. V., Mingozzi, F., Orange, J. S., & High, K. A.
- Affiliations
- Children's Hospital of Philadelphia (US)
- Corresponding author
- High, Katherine A.
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2009-06-01
- Volume
- 119
- Issue
- 6
- Pages
- 1688-1695
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC2689109
- OpenAlex
- W2131862356
- Cited by
- 192
- References
- 51
- Citations by year
- 2026: 5 · 2025: 6 · 2024: 13 · 2023: 10 · 2022: 13 · 2021: 10 · 2020: 12 · 2019: 9 · 2018: 10 · 2017: 15 · 2016: 8 · 2015: 13 · 2014: 13 · 2013: 13 · 2012: 11
- FWCI
- 8.07
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Howard Hughes Medical Institute
- Children's Hospital of Philadelphia
- National Institutes of Health (AI067946)
- National Heart, Lung, and Blood Institute (P01HL078810, T32HL007439, T32HL007150)
- National Institute of Allergy and Infectious Diseases (R01 AI067946S1, R01AI067946)
- National Institute of Diabetes and Digestive and Kidney Diseases (T32DK007748)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- adeno-associated virus, antigen presentation, hepatocytes, cytotoxic T lymphocytes, T cell-mediated lysis, peptide-MHC class I complexes, AAV2, hemophilia B, hepatic gene transfer, aminotransferase elevation, host immune response
- MeSH terms
- Dependovirus, Cell Line, Cytotoxicity, Immunologic, Genetic Vectors, Histocompatibility Antigens, Humans, Receptors, Antigen, T-Cell, Solubility, Substrate Specificity, T-Lymphocytes, Cytotoxic, Antigen Presentation, Hepatocytes, Capsid Proteins, Protein Multimerization
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.